Literature DB >> 29757190

Reversing the curse on PPARγ.

Mitchell A Lazar.   

Abstract

Thiazolidinediones (TZDs) are the only antidiabetic drugs that reverse insulin resistance. They have been a valuable asset in the treatment of type 2 diabetes, but their side effects have curtailed widespread use in the clinic. In this issue of the JCI, Kraakman and colleagues provide evidence that deacetylation of the nuclear receptor PPARγ improves the therapeutic index of TZDs. These findings should revitalize the quest to employ insulin sensitization as a first-line approach to managing type 2 diabetes.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29757190      PMCID： PMC5983334          DOI： 10.1172/JCI121392

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  27 in total

Review 1.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

2.  Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site.

Authors:  M Adams; M J Reginato; D Shao; M A Lazar; V K Chatterjee
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

Review 3.  Maturing of the nuclear receptor family.

Authors:  Mitchell A Lazar
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

4.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

Review 5.  An overview of current and emerging SERMs.

Authors:  Barry S Komm; Sebastian Mirkin
Journal:  J Steroid Biochem Mol Biol       Date:  2014-03-22       Impact factor: 4.292

6.  Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma.

Authors:  E Hu; J B Kim; P Sarraf; B M Spiegelman
Journal:  Science       Date:  1996-12-20       Impact factor: 47.728

7.  Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ.

Authors:  Li Qiang; Liheng Wang; Ning Kon; Wenhui Zhao; Sangkyu Lee; Yiying Zhang; Michael Rosenbaum; Yingming Zhao; Wei Gu; Stephen R Farmer; Domenico Accili
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

8.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Authors:  Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder
Journal:  N Engl J Med       Date:  2016-02-17       Impact factor: 91.245

9.  Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

Authors:  Jang Hyun Choi; Alexander S Banks; Theodore M Kamenecka; Scott A Busby; Michael J Chalmers; Naresh Kumar; Dana S Kuruvilla; Youseung Shin; Yuanjun He; John B Bruning; David P Marciano; Michael D Cameron; Dina Laznik; Michael J Jurczak; Stephan C Schürer; Dušica Vidović; Gerald I Shulman; Bruce M Spiegelman; Patrick R Griffin
Journal:  Nature       Date:  2011-09-04       Impact factor: 49.962

10.  Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study.

Authors:  Manuj Sharma; Irwin Nazareth; Irene Petersen
Journal:  BMJ Open       Date:  2016-01-13       Impact factor: 2.692
View more
  5 in total

1.  LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation.

Authors:  Laurent Calvier; Philippe Boucher; Joachim Herz; Georg Hansmann
Journal:  Circ Res       Date:  2019-04-26       Impact factor: 17.367

Review 2.  Activation of the Metabolic Master Regulator PPARγ: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.

Authors:  Georg Hansmann; Laurent Calvier; Michael G Risbano; Stephen Y Chan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

3.  The Suv420h histone methyltransferases regulate PPAR-γ and energy expenditure in response to environmental stimuli.

Authors:  Simona Pedrotti; Roberta Caccia; Maria Victoria Neguembor; Jose Manuel Garcia-Manteiga; Giulia Ferri; Clara de Palma; Tamara Canu; Matteo Giovarelli; Paolo Marra; Amleto Fiocchi; Ivan Molineris; Michele Raso; Francesca Sanvito; Claudio Doglioni; Antonio Esposito; Emilio Clementi; Davide Gabellini
Journal:  Sci Adv       Date:  2019-04-17       Impact factor: 14.136

4.  PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment.

Authors:  Longhua Liu; Lihong Fan; Michelle Chan; Michael J Kraakman; Jing Yang; Yong Fan; Nicole Aaron; Qianfen Wan; Maria Alicia Carrillo-Sepulveda; Alan R Tall; Ira Tabas; Domenico Accili; Li Qiang
Journal:  Diabetes       Date:  2020-05-14       Impact factor: 9.337

Review 5.  Trace Elements, PPARs, and Metabolic Syndrome.

Authors:  Yujie Shi; Yixin Zou; Ziyue Shen; Yonghong Xiong; Wenxiang Zhang; Chang Liu; Siyu Chen
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.